Triple-negative breast cancer (TNBC), a heterogeneous and therapeutically challenging subtype, comprises over 50% of patients categorized into basal-like 1 (BL1) and basal-like 2 (BL2) intrinsic molecular subtypes. Despite their shared basal-like classification, BL2 is associated with a poor response to neoadjuvant chemotherapy and reduced relapse-free survival compared to BL1. Here, the study focused on identifying subtype-specific markers for BL2 through transcriptomic analysis of TNBC patients using RNA-seq and clinical integration. Six receptor tyrosine kinase (TK) genes, including EGFR, EPHA4, EPHB2, PDGFRA, PDGFRB, and ROR1, were identified as potential differentiators for BL2. Correlations between TK mRNA expression and TNBC prognosis, particularly EGFR, PDGFRA, and PDGFRB, revealed potential synergistic interactions in pathways related to cell survival and proliferation. Our findings also suggest promising dual markers for predicting disease prognosis. Furthermore, RT-qPCR validation demonstrated that identified BL2-specific TKs were expressed at a higher level in BL2 than in BL1 cell lines, providing insights into unique characteristics. This study advances the understanding of TNBC heterogeneity within the basal-like subtypes, which could lead to novel clinical treatment approaches and the development of targeted therapies.
Triple negative breast cancer (TNBC) shows impediment to the development of targeted therapies due to the absence of specific molecular targets. The high heterogeneity across TNBC subtypes, which can be classified to be at least four subtypes, including two basal-like (BL1, BL2), a mesenchymal (M), and a luminal androgen receptor (LAR) subtype, limits the response to cancer therapies. Despite many attempts to identify TNBC biomarkers, there are currently no effective targeted therapies against this malignancy. In this study, thus, we identified the potential tyrosine kinase (TK) genes that are uniquely expressed in each TNBC subtype, since TKs have been typically used as drug targets. Differentially expressed TK genes were analyzed from The Cancer Genome Atlas (TCGA) database and were confirmed with the other datasets of both TNBC patients and cell lines. The results revealed that each TNBC subtype expressed distinct TK genes that were specific to the TNBC subtype. The identified subtype-specific TK genes of BL1, BL2, M, and LAR are LYN, CSF1R, FGRF2, and SRMS, respectively. These findings could serve as a potential biomarker of specific TNBC subtypes, which could lead to an effective treatment for TNBC patients.
Background/Objectives: Urothelial carcinoma of the bladder (UCC) is a leading cause of cancer-related death globally. Given that urine is in direct contact with the tumor, it represents a highly valuable source for non-invasive molecular analysis. Methods: This study utilized liquid biopsies from 41 UCC patients and 27 non-cancerous hematuria controls to identify novel diagnostic and prognostic biomarkers via proteomic and transcriptomic analysis. Results: Urine proved to be a reliable source, yielding a mean tumor cell fraction of 0.605 (95% CI: 0.505–0.705). We identified 11 genes with concurrent alteration at both the urinary protein and mRNA levels. Notably, four upregulated markers, CYTB, C1QC, SBP1, and ANXA4, demonstrated strong diagnostic potential, with AUC values greater than 0.70. CYTB and ANXA4 were detectable even in early-stage UCC (stages Cis, I, and II). Furthermore, we identified two proteins, CATC and SPB10, that were markedly upregulated in recurrent UCC and correlated with poor overall survival, positioning them as potential prognostic markers for recurrence risk. Conclusions: This study confirms the utility of urine as a reliable medium for detecting UCC tumor cells, offering promising markers for both early-stage diagnosis and predicting NMIBC recurrence.
Primary aldosteronism (PA) typically presents with hypertension and hypokalemia; however, its presentation as life-threatening ventricular arrhythmias is rare and often underrecognized. We report a case of a 30-year-old woman who presented with polymorphic ventricular tachycardia manifesting as torsades de pointes. Laboratory findings revealed persistent hypokalemia, metabolic alkalosis, suppressed renin, and inappropriately elevated aldosterone. Because recurrent malignant arrhythmia conferred a high immediate risk of sudden cardiac death, genetic testing for inherited arrhythmia syndromes was initiated, and an implantable cardioverter-defibrillator was implanted for secondary prevention before genetic confirmation became available. Endocrine evaluation proceeded concurrently and ultimately established the diagnosis of PA. Subsequent genetic analysis identified a pathogenic splice-site variant in KCNH2, consistent with congenital long QT syndrome type 2 (LQTS2). A review of the literature identified 16 previously reported cases of PA-associated ventricular arrhythmia, which showed a consistent association with hypokalemia and hypertension; however, none included genetic evaluation. This case highlights the need for parallel endocrine and arrhythmia evaluation in patients with unexplained ventricular arrhythmias.